{"entity": "researcher", "timestamp": "2026-09-29T16:14:35.135Z", "family": "Palma", "given": "Marzia", "initials": "M", "orcid": "0000-0003-4287-3179", "affiliations": ["Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.", "Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/fc1dd22fd3ca4eb3823866960fd240d2.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/fc1dd22fd3ca4eb3823866960fd240d2"}}, "publications": [{"entity": "publication", "iuid": "7f676fd1be9f42038b0f4639f4f3cba5", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7f676fd1be9f42038b0f4639f4f3cba5.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7f676fd1be9f42038b0f4639f4f3cba5"}}, "title": "Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.", "authors": [{"family": "Blixt", "given": "Lisa", "initials": "L"}, {"family": "Bogdanovic", "given": "Gordana", "initials": "G"}, {"family": "Buggert", "given": "Marcus", "initials": "M"}, {"family": "Gao", "given": "Yu", "initials": "Y"}, {"family": "Hober", "given": "Sophia", "initials": "S"}, {"family": "Healy", "given": "Katie", "initials": "K"}, {"family": "Johansson", "given": "Hemming", "initials": "H"}, {"family": "Kjellander", "given": "Christian", "initials": "C"}, {"family": "Mravinacova", "given": "Sara", "initials": "S", "orcid": "0000-0003-1848-910X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c1e48837666642b18a977bb8a8c39603.json"}}, {"family": "Muschiol", "given": "Sandra", "initials": "S"}, {"family": "Nilsson", "given": "Peter", "initials": "P", "orcid": "0000-0002-4657-8532", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3db33fa3edb94febb8be7927a16838d0.json"}}, {"family": "Palma", "given": "Marzia", "initials": "M", "orcid": "0000-0003-4287-3179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fc1dd22fd3ca4eb3823866960fd240d2.json"}}, {"family": "Pin", "given": "Elisa", "initials": "E"}, {"family": "Smith", "given": "C I Edvard", "initials": "CIE", "orcid": "0000-0003-1907-3392", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/357ca5f9684948fb89f138da8c2c9aa2.json"}}, {"family": "Stromberg", "given": "Olga", "initials": "O"}, {"family": "S\u00e4llberg Chen", "given": "Margaret", "initials": "M", "orcid": "0000-0002-3793-4064", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/76491dcd7c2e462dbd3a21a98fe04e16.json"}}, {"family": "Zain", "given": "Rula", "initials": "R", "orcid": "0000-0001-8327-846X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/269ea37f5bd841c2921dc4a5eddc7e41.json"}}, {"family": "Hansson", "given": "Lotta", "initials": "L", "orcid": "0000-0001-6614-5737", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ad4bcbe463b0417e92258dbf5cb14886.json"}}, {"family": "\u00d6sterborg", "given": "Anders", "initials": "A", "orcid": "0000-0001-6489-4865", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/20620d6f76924b4a82239eb57061bd67.json"}}], "type": "journal article", "published": "2022-02-00", "journal": {"title": "Leukemia", "issn": "1476-5551", "volume": "36", "issue": "2", "pages": "476-481", "issn-l": "0887-6924"}, "abstract": "We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during month 1-13 of the pandemic. Sixty patients (median age 71 y, range 43-97) were identified. Median CIRS was eight (4-20). Patients had indolent CLL (n = 38), had completed (n = 12) or ongoing therapy (n = 10). Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 were admitted to ICU. Severe Covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except CIRS (p < 0.05). Fourteen patients (23%) died; age \u226575 y was the only significant risk factor (p < 0.05, multivariate analysis with limited power). Comparing month 1-6 vs 7-13 of the pandemic, deaths were numerically reduced from 32% to 18%, ICU admission from 37% to 15% whereas hospitalizations remained frequent (86% vs 71%). Seroconversion occurred in 33/40 patients (82%) and anti-SARS-CoV-2 antibodies were detectable at six and 12 months in 17/22 and 8/11 patients, respectively. Most (13/17) had neutralizing antibodies and 19/28 had antibodies in saliva. SARS-CoV-2-specific T-cells (ELISpot) were detected in 14/17 patients. Covid-19 continued to result in high admission even among consecutive and young early- stage CLL patients. A robust and durable B and/or T cell immunity was observed in most convalescents.", "doi": "10.1038/s41375-021-01424-w", "pmid": "34564699", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8475381"}, {"db": "pii", "key": "10.1038/s41375-021-01424-w"}], "notes": [], "created": "2026-09-23T09:34:15.148Z", "modified": "2026-09-23T09:34:15.318Z"}, {"entity": "publication", "iuid": "7d6479590a2f404896c516cacf3321ec", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7d6479590a2f404896c516cacf3321ec.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7d6479590a2f404896c516cacf3321ec"}}, "title": "Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.", "authors": [{"family": "Palma", "given": "Marzia", "initials": "M", "orcid": "0000-0003-4287-3179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fc1dd22fd3ca4eb3823866960fd240d2.json"}}, {"family": "Krstic", "given": "Aleksandra", "initials": "A"}, {"family": "Pe\u00f1a Perez", "given": "Lucia", "initials": "L"}, {"family": "Bergl\u00f6f", "given": "Anna", "initials": "A"}, {"family": "Meinke", "given": "Stephan", "initials": "S"}, {"family": "Wang", "given": "Qing", "initials": "Q"}, {"family": "Blomberg", "given": "K Emelie M", "initials": "KEM"}, {"family": "Kamali-Moghaddam", "given": "Masood", "initials": "M"}, {"family": "Shen", "given": "Qiujin", "initials": "Q"}, {"family": "Jaremko", "given": "Georg", "initials": "G"}, {"family": "Lundin", "given": "Jeanette", "initials": "J"}, {"family": "De Paepe", "given": "Ayla", "initials": "A"}, {"family": "H\u00f6glund", "given": "Petter", "initials": "P"}, {"family": "Kimby", "given": "Eva", "initials": "E"}, {"family": "\u00d6sterborg", "given": "Anders", "initials": "A"}, {"family": "M\u00e5nsson", "given": "Robert", "initials": "R"}, {"family": "Smith", "given": "C I Edvard", "initials": "CIE"}], "type": "journal article", "published": "2018-10-00", "journal": {"title": "Br. J. Haematol.", "issn": "1365-2141", "volume": "183", "issue": "2", "pages": "212-224", "issn-l": "0007-1048"}, "abstract": "In chronic lymphocytic leukaemia (CLL) patients, treatment with the Bruton tyrosine kinase inhibitor ibrutinib induces a rapid shift of tumour cells from lymph nodes (LN) to peripheral blood (PB). Here, we characterized in depth the dynamics of ibrutinib-induced inflammatory, transcriptional and cellular changes in different compartments immediately after treatment initiation in seven relapsed/refractory CLL patients. Serial PB and LN samples were taken before start and during the first 29 days of treatment. Changes in plasma inflammation-related biomarkers, CLL cell RNA expression, B-cell activation and migration markers expression, and PB mononuclear cell populations were assessed. A significant reduction of 10 plasma inflammation markers, the majority of which were chemokines and not CLL-derived, was observed within hours, and was paralleled by very early increase of CD19+ circulating cells. At the RNA level, significant and continuous changes in transcription factors and signalling molecules linked to B-cell receptor signalling and CLL biology was observed in both PB and LN CLL cells already after 2 days of treatment. In conclusion, ibrutinib seems to instantly shut off an ongoing inflammatory response and interfere with diverse sensitive pathways in the LN.", "doi": "10.1111/bjh.15516", "pmid": "30125946", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T11:49:13.814Z", "modified": "2026-09-23T11:49:13.830Z"}]}